RANKL


Also found in: Acronyms, Encyclopedia, Wikipedia.

RANKL

(rank'ĕl),
Abbreviation for receptor activator of nuclear factor-κB.

RANKL

, RANK ligand
Thereceptor activator of nuclear factor kappa B ligand, a chemical produced by osteoblasts that causes osteoclasts to proliferate and break down both the cortex and the trabecula of bone.

Excessive activity of this chemical produces pathological bone loss, e.g., in some forms of inflammatory arthritis and in some diseases in which cancers metastasize to bone.

References in periodicals archive ?
Loss of Nrf2 accelerates ionizing radiation-induced bone loss by upregulating RANKL.
Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Furthermore, promotion of osteoblast differentiation reduced RANKL expression and inhibited the ability of the cells to support osteoclast differentiation (18,19); osteoblast expression of the RANKL/OPG ratio was much higher in less mature osteoblasts than in mature ones (19).
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis.
To find the proteins' role in the brain, Reiko Hanada, a member of Penninger's group, injected RANKL into the brains of rats and mice.
Vitamin D3 augments osteoclastogenesis via vitamin D responsive element on mouse RANKL gene promoter.
Cells were cultured in [alpha]-MEM with 10% FBS supplemented with M-CSF (30 ng/mL), RANKL (100 ng/mL), 1% L-glutamine, 1% penicillin/streptomycin, and 1% nonessential amino acids (Gibco).
Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K).
RANKL is secreted by osteoblasts, bone marrow cells and lymphocytes, a process that increases in the acute deficiency of oestrogen that occurs in menopause.
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you see forecasts to 2024 for these three submarkets and their respective segments: -- Antiresorptive Drugs - Bisphosphonates - Selective Oestrogen Receptor Modulators (SERMs) - RANKL Antibodies - Cathepsin K Inhibitors - Other antiresorptive drugs -- Anabolic Drugs - Human Recombinant Parathyroid Hormones - Anti-Sclerostin monoclonal antibodies -- Other osteoporosis treatments